- 29
- 0
- 约6.17千字
- 约 10页
- 2018-10-05 发布于湖北
- 举报
阿托伐他汀钙对冠心病患者尿蛋白及肾功能的影响
【摘要】目的探究阿托伐他汀?}对冠心病患者的尿蛋白及肾功能的影响。
方法选取2015年6月至2016年6月收治的冠心病合并肾功能损害及蛋白尿患者68例,按照随机分配的原则分为两组。对照组34例予以冠心病常规治疗(包括抗血小板聚集,应用硝酸酯类、β受体阻滞剂、血管紧张素转换酶抑制剂等药物治疗,对伴有内科合并症者给予相应的降压、降糖治疗);观察组34例在常规治疗基础上加阿托伐他汀钙 20 mg qn。观察治疗前、治疗后12周及半年患者的24小时尿微量白蛋白(MAU)、肌酐(Cr)、尿素氮(BUN)变化。
结果经过12周治疗后,观察组24小时MAU、Cr和BUN变化优于对照组,但差异无统计学意义(P0.05);经过半年治疗后,观察组24小时MAU、Cr和BUN变化优于对照组,差异有统计学意义(P0.05或0.01)。
结论阿托伐他汀钙能够有效降低冠心病患者的尿白蛋白、肌酐和尿素氮,对冠心病患者的肾功能起到明显的改善作用,值得临床推广应用。
【关键词】阿托伐他汀钙;冠心病;尿微量白蛋白;肾功能
中图分类号:R541.6文献标识码:ADOI:10.3969/j.issn2017.01.008
A study on impact of atorvastatin calcium on urine protein and renal function of patients with coronary heart disease
[HJ1*2][HJ]
ZHANG Yingliang,LIANG Shiwen,ZHOU Guojun
(Department of Cardiovascular Medicine,No.9 People’s Hospital of Nanning,Nanning 530409,China)
[HJ2][HJ]
【Abstract】Objective To explore impact of atorvastatin calcium on urine protein and renal function of patients with coronary heart disease(CHD).
Methods68 cases of CHD combined with renal impairment and proteinuria(MAU) admitted to hospital from June,2015 to June,2016 were selected to this study,and they were randomly divided into observation group and control group.The control group(34 cases) were given CHD conventional treatment,that was to resist platelet aggregation,to apply nitrates,β blockers,angiotensin converting enzyme inhibitor(ACEI) to provide appropriate antihypertensive and hypoglycemic therapy to cases of CHD combined with medical complications.The observation group (34 cases) were added 20 mg qn of atorvastatin calcium in the basis of conventional treatment.And then,changes of 24 h microalbumin(MAU),creatinine(Cr) and blood urea nitrogen(BUN) before treatment,12 weeks and 6 months after treatment were compared.
ResultsAfter 12 weeks of treatment,changes of 24 h MAU,Cr and BUN of the observation group were significantly better than those of the control group,but difference was not statistically significant(P0.05).After
原创力文档

文档评论(0)